▮ Slide Shows

▮ Entertainment

Top Stories
Game of Thrones
▮ Music news
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

▮ Content Licensing

▮ Premium NEW

▮ More

Intraday Alerts

Siyata Mobile Shares Gain 40%

By RTTNews Staff Writer ✉ | Published: 12/31/2021 11:50 AM ET

Shares of Siyata Mobile Inc. (SYTA) are gaining over 40% on Friday morning despite no stock-specific news to drive the shares.

SYTA is currently trading at $4.34, up $1.26 or 40.9091%, on the Nasdaq.

Siyata Mobile Inc. develops and provides cellular communications solutions for enterprise customers.

For comments and feedback contact: editorial@rttnews.com

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

Biotech Stocks Facing FDA Decision In June 2023

Biotech Stocks Facing FDA Decision In June 2023

Biotech Stocks Facing FDA Decision In April 2023

Biotech Stocks Facing FDA Decision In April 2023

Biotech Stocks Facing FDA Decision In March 2023

Biotech Stocks Facing FDA Decision In March 2023

Latest Updates on COVID-19

FDA Approves Pfizer's COVID-19 Pill Paxlovid

US Revokes Covid Vaccination Requirement For International Air Travel

Read More

COVID-19: Drugs in Development

Follow RTT

Editor's Pick
Most Read
Most Emailed

Inditex Stock Up On Q1 Profit Growth; Sees Flat Margin In FY23

CPSC Warns Against Recalled Boppy Newborn Loungers After More Infant Deaths

Apple Unveils Vision Pro Headset, IOS 17, 15-inch MacBook Air And More

Domino's Offers 50% Off Online Deal Through June 11

Frozen RTE Beef Chili Products Supplied Through NSLP Recalled

Boeing, NASA Further Delay Starliner Crew Flight Launch

Chervon Recalls EGO Power+ Cordless Brushless Hedge Trimmers

E.N.A. Meat Packing Recalls Frozen, Raw Lamb Products

Dechra Pharma Agrees To Be Acquired By EQT's Freya Bidco For 3,875p/share In Cash

AstraZeneca Reports Positive Results From Interim Analysis Of DESTINY-PanTumor02 Phase II Trial

Novartis Says Kisqali And Endocrine Therapy Reduces Cancer Recurrence Risk By 25%

Novavax Signs Deal With Bill & Melinda Gates Research Institute To Provide Matrix-M Adjuvant

MorphoSys To Release Myelofibrosis Trial Data This Year

MEI Pharma Promotes COO David Urso To Succeed Daniel Gold As President And CEO

Evotec Gets $1.7 Mln Grant For Discovery Of RNA-targeting Henipavirus Therapeutics

Bellerophon Therapeutics: Phase 3 REBUILD Trial Fails To Meet Primary Endpoint

CIRCOR Int'l To Be Taken Private By KKR In $1.6 Bln All-cash Deal

Barnes Group To Acquire MB Aerospace

Foghorn : FDA Lifts Clinical Hold On Phase 1 Study Of FHD-286 In Relapsed And/or Refractory AML/MDS

Hoth Therapeutics' Alzheimer's Disease Drug Yields Positive Results In Preclinical Study

Horizon Therapeutics And KPMG Women's Irish Open Form Exclusive Partnership

Foghorn : FDA Lifts Clinical Hold On Phase 1 Study Of FHD-286 In Relapsed And/or Refractory AML/MDS

Inditex Stock Up On Q1 Profit Growth; Sees Flat Margin In FY23

Evotec Gets $1.7 Mln Grant For Discovery Of RNA-targeting Henipavirus Therapeutics

NatWest Completes Sale Of EUR 55.2 Mln Of Shares In Permanent TSB

EU Commissioner Jourova Calls For Labeling Of AI-generated Content

G-III APPAREL Q1 Profit Down, But Beats Estimates; Revises Up Annual Outlook; Stock Up - Update

Paragon Bank H1 Earnings Fall, But Revenues Rise

Frozen RTE Beef Chili Products Supplied Through NSLP Recalled

Accenture Unit Gets $329 Mln Contract From USAID - Quick Facts

Boeing, NASA Further Delay Starliner Crew Flight Launch

Novartis Says Kisqali And Endocrine Therapy Reduces Cancer Recurrence Risk By 25%